FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
174 letters match. Newest first.
-
DrugsShenzhen Benliju Biotech Co., Ltd.
FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.
High risk -
FoodMseafood Corporation
Mseafood Corporation lacked required foreign supplier verification for imported cocktail sauce, FDA says.
Medium -
DrugsJiangmen Shuizirun Sanitary Articles Co., Ltd.
FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.
High risk -
DrugsSCA Pharmaceuticals, LLC
SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
DrugsPine Pharmaceuticals, LLC
FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.
High risk -
DrugsFresenius Kabi USA LLC
FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.
High risk -
FoodUnion Trade Inc.
FDA warns Union Trade Inc. that it lacked required foreign supplier verification for imported radish, peanuts, mushrooms, and fruit.
High risk -
DrugsPReye, LLC
FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DrugsSafrel Pharmaceuticals LLC
FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.
High risk -
DrugsLico Industries, LLC., d.b.a. American Towelette Company
FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.
High risk -
FoodJ&B Food Consulting
J&B Food Consulting lacked a Foreign Supplier Verification Program for imported pet treats; some samples had Salmonella.
High risk -
DrugsExcelvision - Fareva
FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.
High risk -
DrugsFagron BV
FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.
High risk -
DrugsMedline Inc
FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
High risk -
DrugsHealthPartners Neuroscience Center Research and Innovation
FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.
Medium -
DrugsIDO Pharm Co., Ltd.
IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.
High risk -
DrugsAva Inc.
FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
High risk -
FoodNupack Inc.
FDA warned Nupack Inc. that its dietary supplements were unapproved drugs and made without required manufacturing-practice records.
High risk -
DrugsRC Outsourcing, LLC
FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.
High risk -
DrugsApollo Care, LLC
FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.
High risk -
DrugsMedical Products Laboratories, Inc.
Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.
High risk -
DevicesLonghorn Vaccines and Diagnostics LLC
Longhorn Vaccines and Diagnostics sold its PrimeStore MTM sample transport device without required quality controls or clearance for claims beyond its approved uses.
High risk -
DrugsApothecary Pharma, LLC
FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.
High risk -
DrugsNovo Nordisk Inc.
FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.
High risk -
FoodEl Rey USA Meats & Seafood Inc.
FDA found El Rey USA Meats & Seafood lacked required importer verification for shrimp and tilapia.
High risk -
DrugsGenoGenix LLC
FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.
High risk -
DrugsA. Nelson & Co. Ltd.
London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.
High risk -
DrugsAQ USA Inc., d.b.a Ross Healthcare Inc.
FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.
High risk -
DrugsMedisourceRx
MedisourceRx failed to report a serious adverse event and had inadequate procedures, so its compounded drugs lost legal exemptions.
Medium -
DrugsBio-Medical Pharmaceutical Manufacturing Corporation
Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.
High risk -
BiologicsCentral Coast Multispecialty Medical Group, Inc.
FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.
High risk -
BiologicsConceive Fertility Center
FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.
High risk -
DrugsCDL Services, Inc. DBA Technichem
FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.
High risk -
DrugsDeVere Manufacturing Inc.
FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.
High risk -
DrugsPQ Pharmacy, LLC
FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.
High risk -
DrugsTurbare Manufacturing
FDA warns outsourcing facility Turbare Manufacturing of Conway, Arkansas, for making sterile drugs under insanitary conditions.
High risk -
DrugsWells Pharma of Houston, LLC
FDA warns Wells Pharma of Houston over sterile compounded drugs made under insanitary conditions.
High risk -
DrugsMiers Laboratories, Ltd
FDA warns Miers Laboratories over manufacturing violations and places import alert on its drugs.
High risk -
DrugsKath Khemicals LLC
FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.
High risk -
DevicesLEVO AG
FDA says LEVO AG lacked a quality system, adverse-event reporting procedures, and device ID data for standup wheelchairs.
High risk -
DrugsHealth and Natural Beauty USA Corp.
FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.
High risk -
FoodVidaslim Co.
Vidaslim Co. dietary supplements are adulterated by CGMP failures and misbranded by label violations.
Medium -
DrugsYangzhou Yulou Paper Products Co., Ltd.
FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.
High risk -
DrugsSomerset Therapeutics Private Limited
FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.
High risk -
FoodDingMoo LLC DBA Dingman’s Dairy
DingMoo LLC DBA Dingman’s Dairy lacked Foreign Supplier Verification Program records for imported frozen desserts and Pistachio Tartufo tied to a Salmonella outbreak.
High risk -
FoodMericon Industries, Inc.
Mericon Industries sold Florical and Meribin supplements with unapproved drug claims for osteoporosis and serious manufacturing and labeling failures.
High risk -
DrugsDaewoo Pharmaceutical Co., Ltd.
FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.
High risk